ABSTRACT
BACKGROUND Little is known about the trajectory over time of neurologic recovery after traumatic brain injury (TBI). We sought to determine long-term changes in neurologic status after prehospital clinical trial interventions for acute TBI.
METHODS We used data from the Resuscitation Outcomes Consortium Hypertonic Saline (ROC HS) TBI Trial. The trial included adult TBI, with Glasgow Coma Scale (GCS)≤8 and excluded those with shock (systolic blood pressure (SBP)≤70, or SBP 71-90 with HR≥108). The primary outcome was Glasgow Outcome Scale-Extended (GOS-E; 1=dead, 8=no disability) determined at: a) hospital discharge and b) 6-month follow-up. We analyzed changes in GOS-E between hospital discharge and 6-month follow-up by examining median changes with exact 95% confidence intervals (CI), mean changes with bootstrapped 95% CIs and Sankey graphs. We repeated the analysis for the high acuity subset of patients undergoing prehospital advanced airway insertion.
RESULTS Among 1,279 TBI subjects included in the analysis, GOS-E categories at hospital discharge were: favorable (GOS-E 5-8) 220 (17.2%), unfavorable (GOS-E 2-4) 664 (51.9%), dead (GOS-E 1) 321 (25.1%), missing 74 (5.8%). GOS-E categories at 6-month follow-up were: favorable 459 (35.9%), unfavorable 279 (21.8%), dead 346 (27.1%), missing 195 (15.2%). Among initial TBI survivors with complete GOS-E, >96% followed one of three neurologic recovery trajectories: 1) favorable to favorable (20.0%), 2) unfavorable to favorable (40.3%), and 3) unfavorable to unfavorable (36.0%). Few patients deteriorated from favorable to unfavorable neurologic status and there were few additional deaths.
CONCLUSION Neurologic recovery after TBI follows distinct trajectories. Among those with TBI and unfavorable neurologic status at hospital discharge, almost half will improve to favorable neurologic status at six months. Among those with favorable neurologic status at discharge, very few worsen to unfavorable neurologic status or death at six months. These findings have important implications for TBI clinical care, research and trial design.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Arizona gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data for this study may be requested from the NHLBI BioLINCC repository.
